AstraZeneca PLC (AZN)vsTriSalus Life Sciences Inc. (TLSI)
AZN
AstraZeneca PLC
$185.95
+0.81%
HEALTHCARE · Cap: $282.69B
TLSI
TriSalus Life Sciences Inc.
$3.30
+3.77%
HEALTHCARE · Cap: $223.56M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 134559% more annual revenue ($60.44B vs $44.88M). AZN leads profitability with a 17.2% profit margin vs -60.9%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
TLSI
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for TLSI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Trading at 15.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -496.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : TLSI
TLSI has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : TLSI
The primary concerns for TLSI are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.69 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while TLSI is a turnaround play — different risk/reward profiles.
TLSI carries more volatility with a beta of 0.49 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 16/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
TriSalus Life Sciences Inc.
HEALTHCARE · MEDICAL DEVICES · USA
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical company focused on revolutionizing cancer treatment through its proprietary localized drug delivery systems. By enhancing the effectiveness of immuno-oncology agents and overcoming distribution challenges within tumor microenvironments, TriSalus is dedicated to improving therapeutic outcomes for cancer patients. With a promising pipeline of clinical programs, the company aims to meet the urgent demand for advanced cancer therapies. Positioned strategically within the dynamic oncology landscape, TriSalus is poised for significant impact as it seeks to expand access to its groundbreaking treatments.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?